This event has passed. ×

Efficacy of AAV-Mediated Gene Replacement Therapy for MYBPC3-Related Hypertrophic Cardiomyopathy

  • Friday, October 8, 2021
  • 1:30 PM–2:30 PM

Join the students of BIO295 ("Biology Seminar") as we welcome speakers from a variety of locations with a great array of experiences to our campus. Join us as we learn about their unique backgrounds and work within the field of Biology.

"Efficacy of AAV-Mediated Gene Replacement Therapy for MYBPC3-Related Hypertrophic Cardiomyopathy"

Guest Speaker: Marian Henderson - Student, Calvin University

Friday, Oct. 8th, 2021

1:30p - 2:20p

*Science Building (SB) 010 

Hypertrophic cardiomyopathy (HCM) is a highly morbid myocardial disease with a high prevalence in the general population. The most common genetic cause of HCM are mutations in cardiac myosin binding protein C (MyBP-C), encoded for by MYBPC3. This project, conducted in the lab of Dr. Adam Helms as part of the Frankel Cardiovascular Center Summer Undergraduate Research Fellowship, tested the efficacy of an AAV-mediated gene replacement therapy for HCM. This treatment was tested in human induced pluripotent stem cell-derived cardiomyocytes plated on 2D microtissue constructs. Analyses of tissue contractility and protein expression, quantified through alternative immunofluorescence intensity, were used to determine the effectiveness of the treatment.

Any questions? Please contact Erika Purcell-Williams ( for further assistance.

October 2021
Sun Mon Tue Wed Thu Fri Sat

View Today
Event quick search
Share this event
Add to calendar